Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00221741
Other study ID # 9293-02
Secondary ID 2002-006
Status Completed
Phase N/A
First received September 13, 2005
Last updated March 17, 2015
Start date February 2004
Est. completion date March 2006

Study information

Verified date March 2015
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Observational

Clinical Trial Summary

Despite experts' recommendations, the consumption of Fresh frozen plasma (FFP) is very heterogeneous among French cardiac surgery centers. This probably reflects heterogeneous practices that are not characterized and whose outcomes on morbidity and mortality are not documented.

The principal objective of the study is to describe transfusional strategies of FFP in patients undergoing cardiac surgery. The other objectives are: to assess the conformity of FFP transfusion or lack of transfusion to current French authorities' recommendations, to describe the post-operative mortality and morbidity and to assess the prognostic role of FFP on mortality and morbidity. Prognostic analyses will take into account other prognostic factors of mortality and morbidity.

1500 patients undergoing cardiac surgery and presenting with a serious bleeding (or transfused with FFP without bleeding) will be included in the study.


Description:

Background

Fresh frozen plasma (FFP) transfusions recommendations are essentially based on experts' opinions. However, disparity in consumption of FFP by cardiac surgery centers in France probably reflects heterogeneous practices that are not well characterized. Furthermore, health outcomes of these strategies on morbidity and mortality are not documented.

Objectives

Primary: to describe transfusional strategies of FFP in patients undergoing cardiac surgery and either presenting a serious bleeding during pre, per or post-operative periods or transfused by FFP without a serious bleeding.

Secondary:

- To estimate the conformity of transfusion or lack of transfusion of FFP to French authorities recommendations.

- To describe the post-operative mortality and morbidity.

- To evaluate the prognostic role of FFP transfusion on mortality and morbidity

Study design

Prospective prognostic cohort study, with an exhaustive recruitment in participating cardiac surgery centers during the study period.

Eligibility criteria

Centers: 16 French cardiac surgery centers.

Patients:

- Coronary artery bypass grafting (CABG), valvular replacement, surgery for thoracic aorta aneurysm or dissection, heart graft.

- Serious bleeding or FFP transfusion during pre, per or post-operative period.

- Patient's consent for collecting medical data

Analysis

Descriptive analysis of transfusional strategies according to patients' characteristics, type of surgery and circumstances of transfusions.

Conformity to French authorities' current recommendations. Multivariate analysis of the prognostic role of FFP transfusion on 30-day mortality.


Recruitment information / eligibility

Status Completed
Enrollment 1497
Est. completion date March 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Coronary artery bypass grafting (CABG), valvular replacement, surgery for thoracic aorta aneurysm or dissection, heart graft.

- Serious bleeding or FFP transfusion during pre, per or post-operative periods.

- Patient's consent for collecting medical data

Exclusion Criteria:

- Congenital heart disease

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
Fresh Frozen Plasma (blood product)


Locations

Country Name City State
France Département d'anesthésie-réanimation II (DAR II), Hôpital Haut-Lévêque, Av de Magellan Pessac

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

See also
  Status Clinical Trial Phase
Completed NCT04114253 - QStat in Liver Transplant
Recruiting NCT05077124 - Safe and Timely Antithrombotic Removal (STAR) Registry
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Completed NCT02043132 - Tranexamic Acid in Reverse Total Shoulder Arthroplasty Phase 2/Phase 3
Withdrawn NCT00861367 - Prospective Double-blind Study for the Use of Aspirin During Transurethral Surgery of the Bladder or the Prostate N/A
Terminated NCT03246919 - Ideal Time of Oxytocin Infusion During Cesarean Section Phase 4
Completed NCT04443920 - Tranexamic Acid for Total Knee Arthroscopy Phase 4
Withdrawn NCT04933253 - Mediastinal Temperature and Post-operative Bleeding N/A
Recruiting NCT02938962 - Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X) Phase 4
Recruiting NCT02130752 - Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery N/A
Recruiting NCT05164809 - Effect of Electrosurgery on Blood Loss and Intraoperative Transfusions in Musculoskeletal Tumor Surgery
Not yet recruiting NCT04574128 - Retransfusion or Not of Cardiotomy Blood N/A
Completed NCT02911831 - IV Tranexamic Acid Prior to Hysterectomy Early Phase 1
Completed NCT02740374 - Evaluation of Thromboelastometry (ROTEM) During Spinal Surgery N/A
Enrolling by invitation NCT05474027 - Reducing Hypotensive Anesthesia Use With TXA During Orthognathic Surgery Phase 4
Completed NCT05391607 - Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement Phase 4
Completed NCT03152461 - Evaluation of the Clinical Performance of the Quantra System With the Quantra Surgical Cartridge
Recruiting NCT02441751 - Intraoperative Volume Management and QT Interval
Completed NCT01053169 - Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study) N/A